Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
2004
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei
2004 Standout
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Adding pharmacogenomics to the development of new marine-derived anticancer agents
2006
Gastric cancer
2016 Standout
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
2016
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
2003
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
2003
Drugs from the deep: marine natural products as drug candidates
2003 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
2002
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
2001
Iridium‐Catalyzed Asymmetric Intramolecular Allylic Amidation: Enantioselective Synthesis of Chiral Tetrahydroisoquinolines and Saturated Nitrogen Heterocycles
2011 StandoutNobel
The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies
2002 Standout
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
2008
Marine-derived anticancer agents in clinical trials
2003
Trabectedin for the treatment of breast cancer
2015
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
2001
Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia
2007
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
2008 Standout
Natural products: A continuing source of novel drug leads
2013 Standout
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia
2005
The combination of yondelis and cisplatin is synergistic against human tumor xenografts
2003
Marine natural products
1990 Standout
Drug development from marine natural products
2008 Standout
Parallel and four-step synthesis of natural-product-inspired scaffolds through modular assembly and divergent cyclization
2012 StandoutNobel
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
2008
Trabectedin
2007
Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
2001
Marine pharmacology in 2000: Antitumor and cytotoxic compounds
2003
Tumor Angiogenesis, Macrophages, and Cytokines
2000
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
2003
Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
2009
Marine pharmacology in 2003–2004: Anti-tumour and cytotoxic compounds
2006
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
2008
The Pictet–Spengler Reaction in Nature and in Organic Chemistry
2011 Standout
Renal and Extrarenal Effects of Gum Arabic (Acacia Senegal) - What Can be Learned from Animal Experiments?
2013 Standout
Vascular Endothelial Growth Factor and Angiogenesis
2004 Standout
JNK activation is critical for Aplidin™-induced apoptosis
2004
Soft-Tissue Sarcomas in Adults
2005 Standout
Molecular mechanisms of platinum resistance: still searching for the Achilles? heel
2004
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
2004
Synthesis and antitumor activity of simplified ecteinascidin–saframycin analogs
2005
New Drugs from the Sea
2004
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Marine pharmacology in 2001–2: antitumour and cytotoxic compounds
2004
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Progress in the development and acquisition of anticancer agents from marine sources
2003
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK
2002
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
Cascade Reactions in Total Synthesis
2006 Standout
Analysis of anticancer drugs: A review
2011 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Downregulation of Angiogenin Transcript Levels and Inhibition of Colonic Carcinoma by Gum Arabic (Acacia senegal)
2010
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Antiangiogenic activity of aplidine, a new agent of marine origin
2004
Natural compounds for cancer treatment and prevention
2009 Standout
The first total synthesis and biological evaluation of marine natural products ma’edamines A and B
2012
Solid‐Phase Synthesis of Tetrahydro‐β‐carbolines and Tetrahydroisoquinolines by Stereoselective Intramolecular N‐Carbamyliminium Pictet–Spengler Reactions
2006 StandoutNobel
The inefficiency of incisions of ecteinascidin 743–DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent
2001
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
2007
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
NF-κB: linking inflammation and immunity to cancer development and progression
2005 Standout
ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas
2005
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
2009 Standout
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
2013
Solid-Phase Intramolecular N-Acyliminium Pictet−Spengler Reactions as Crossroads to Scaffold Diversity
2004 StandoutNobel
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
2004
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Natural Product Synthesis Using Multicomponent Reaction Strategies
2009 Standout
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
2008
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Preclinical and clinical results with the natural marine product ET-743
2003
Marine natural products
2015 Standout
Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma
2007
Marine natural products as therapeutic agents: Part 2
2004
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
2007
Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration.
2000
Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological Potential
2007 Standout
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
2002
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
2010
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
2004
Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
2002 Standout
Asymmetric Synthesis of Isoquinoline Alkaloids
2004 Standout
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
2008
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
2001
Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
2002
Marine Microalgae with Anti-Cancer Properties
2018 Standout
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity
2001
Natural product and natural product derived drugs in clinical trials
2014 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
2011
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells
2003
Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
2005
Targeted therapy for advanced renal cell carcinoma
2008
Works of C. Guzmán being referenced
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
2004
Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
2003
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors
2002
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
2009
Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma
1997
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion
2001
Phase I trials with ET-743, a marine derived (MD) anticancer agent
1999
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
2005
Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound
2001
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
2000
Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer
2001
Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study
2006
Angiogenin expression and prognosis in primary breast carcinoma.
1998
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
2001
Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule
2001